Do Transparent Capsule Inhalers Improve Medication Delivery?
Researchers investigated whether transparent capsules in dry powder inhalers improved medication delivery by providing visual feedback to patients.
Tag: Novartis
All
Latest
Do Transparent Capsule Inhalers Improve Medication Delivery?
Researchers investigated whether transparent capsules in dry powder inhalers improved medication delivery by providing visual feedback to patients.
Read More
Omalizumab Reduces Allergic Reactions to Multiple Foods in Youth
The monoclonal antibody treatment significantly increased the amounts of multiple common foods that food-allergic children and adolescents could consume.
Read MoreNovartis Looks at Canakinumab for Early Lung Cancer
After Novartis failed in an attempt to repurpose canakinumab for metastatic non-small cell lung cancer (NSCLC), the Swiss company said it supported continued exploration of the medication in earlier stages of the disease.
Read More
Philip Morris’ Battle to Buy Asthma Drugmaker Vectura
Philip Morris is competing with a US private equity firm to buy the asthma medicine company Vectura.
Read More
Xolair Prefilled Syringe Approved for self-administration
The US FDA has approved Genetech’s Xolair (omalizumab) prefilled syringe for self-injection for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria, and nasal polyps.
Read MoreNovartis to Aid Pfizer COVID-19 Vaccine Production
Pharmaceutical company Novartis will assist Pfizer and BioNTech in the production of their COVID-19 vaccine.
Read More
Propeller Health Sensor Co-packaged with Enerzair Breezhaler in Europe
Novartis will now co-package the Propeller Health digital health platform with Enerzair Breezhaler in Europe.
Read More
Tabrecta Approved for Non-small Cell Lung Cancer
The US FDA has approved Tabrecta (capmatinib) for the treatment of adult patients with non-small cell lung cancer that has spread to other parts of the body.
Read More
Novartis’ Capmatinib Fights Lung Cancer In the Brain
Novartis’ targeted therapy capmatinib can effectively shrink metastasized lung cancer tumors in the brain, according to a study to be presented at the American Association for Cancer Research meeting.
Read More
Novartis Drops Asthma Drug Fevipiprant After Trial Failures
Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped would be a billion-dollar-selling asthma drug, fevipiprant, from its development program after the medicine failed another set of key trials.
Read More
Ultibro Breezhaler Superior to Seretide in Reducing COPD Exacerbations
Novartis AG has announced positive results from Phase III FLAME trial examining the rate of COPD exacerbations.
Read MoreNovartis Gets FDA OK for Two New COPD Treatments
Two COPD therapies from Novartis — Utibron Neohaler and Seebri Neohaler — have been approved by the FDA for the long-term maintenance treatment of airflow obstruction in patients with COPD.
Read More
Foradil Aerolizer to be Discontinued
The FDA says Novartis and Merck have jointly decided to voluntarily discontinue manufacture of Foradil Aerolizer “for business reasons.”
Read MoreFour Respiratory Drugs on Pathway to CE Approval
The European Medicines Agency (EMA) recommended CE approval for four COPD/asthma drugs, including two from GlaxoSmithKline and others from Novartis and Teva Pharmaceuticals.
Read More